Intellectual Property India Publishes Patent Application for 'Glycosyl-Modified Fusion Protein, Nucleic Acid Molecule, Expression Vector, Host Cell And Use' Filed by Kaimi Biomedicine (CHENGDU) Co. Ltd.

MUMBAI, India, Feb. 28 -- Intellectual Property India has published a patent application (202517002980 A) filed by Kaimi Biomedicine (CHENGDU) Co. Ltd., Sichuan, China, on Jan. 13, for 'glycosyl-modified fusion protein, nucleic acid molecule, expression vector, host cell and use.'

Inventor(s) include Shi, Yuenian; Yu, Bo; and Lu, Hanxin.

The application for the patent was published on Feb. 28, under issue no. 09/2025.

According to the abstract released by the Intellectual Property India: "A glycosyl-modified fusion protein, a nucleic acid molecule, an expression vector, a host cell and the use. A glycosyl-modified fusion protein containing a murine Fc variant and a prostate cancer tumor antigen, wherein the murine Fc variant is obtained ...